• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PureTech Appoints Michele Holcomb, PhD, to Board of Directors

    8/22/24 2:00:00 AM ET
    $KE
    $PRTC
    Electrical Products
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KE alert in real time by email

    Strategic healthcare leader brings more than 30 years of global experience to PureTech's Board following notable positions with Cardinal Health, Teva Pharmaceuticals and McKinsey & Company

    PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Michele Holcomb, PhD, will join its board of directors as an independent non-executive director. Dr. Holcomb's appointment will take effect as of September 23, 2024. She brings more than 30 years of expertise leading global healthcare companies through strategic inflection points and preparing innovative programs and portfolios for growth.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240821665245/en/

    PureTech Appoints Michele Holcomb, PhD, to Board of Directors (Photo: Business Wire)

    PureTech Appoints Michele Holcomb, PhD, to Board of Directors (Photo: Business Wire)

    "As PureTech enters its next phase of growth focused on innovating and progressing major advances for patients, Dr. Holcomb brings a wealth of experience to our strategy that's built among highly visible healthcare organizations," said Bharatt Chowrira, PhD, JD, Chief Executive Officer of PureTech. "She has a proven track record of leading transformational growth initiatives and driving organizational progress that will complement our board's exceptional leadership, and we will greatly benefit from Dr. Holcomb's broad biopharma experience as we deliver on our commitment to bring highly innovative and differentiated new medicines to patients and build value for all of our shareholders."

    "PureTech pioneered the hub-and-spoke business model, and its approach successfully combines commercial, scientific and medical expertise towards a highly focused development strategy for each of the therapies in its portfolio," commented Dr. Holcomb. "I am excited and honored to work with my fellow board members and the PureTech management team to guide the Company through the next stage of evolution."

    Dr. Holcomb is a strategic leader with more than 30 years of healthcare experience across biotech, pharmaceuticals and healthcare services. She has served on both public and private boards, and has been a scientist, consultant and executive, driving change through innovation and optimization at key interfaces. In her previous role as EVP, Chief Strategy and Business Development Officer at Cardinal Health, Dr. Holcomb leveraged an enterprise perspective and knowledge of the evolving healthcare landscape to work with the CEO, CFO, and leaders across the Pharmaceutical and Medical segments to define strategies, optimize the portfolio, and identify growth and innovation opportunities. Her team also led the execution and integration of investments, acquisitions, partnerships and divestitures to support Cardinal Health's strategy, as well as drove the enterprise approach to innovation.

    Prior to Cardinal Health, Dr. Holcomb was the Chief Operating Officer of Global R&D and SVP of Strategy, Portfolio, Search and Partnerships at Teva Pharmaceuticals. She also spent 15 years at McKinsey & Company and was a Partner of the Global Pharmaceutical Practice. Dr. Holcomb is a member of the board of directors and chair of the Nominating and ESG (NESG) committee of Kimball Electronics Inc (NASDAQ:KE). She also serves on the board of the Abigail Wexner Research Institute at Nationwide Children's Hospital in Columbus, the BalletMet of Columbus, where she chairs the long-range planning committee and the Liberty Science Center in New Jersey. Dr. Holcomb is a member of the editorial advisory board of Pharmaceutical Executive and has lectured on healthcare strategy at Kellogg (Northwestern), Columbia and Fuqua (Duke) business schools. Dr. Holcomb received a BS in chemistry from Stanford University and a PhD in chemistry from the University of California, Berkeley, and previously worked as an R&D chemist at Ciba-Geigy and Syntex Pharmaceuticals.

    "On behalf of the entire PureTech Board of Directors, I am honored to welcome Dr. Holcomb to our organization," said Raju Kucherlapati, PhD, Chair of the PureTech Board of Directors. "Dr. Holcomb's extensive background in biopharma, coupled with her innovative mindset and unwavering dedication to excellence, positions her as a pivotal addition to our board. Her unique insights and strategic vision will be instrumental as we work to advance our company's mission, and I am confident that her contributions will drive significant value not only for patients but also for our shareholders."

    On joining PureTech's Board of Directors, Dr. Holcomb will become a member of the Audit Committee and Dr. Kucherlapati will step down from the Audit Committee.

    Dr. Holcomb is independent for the purposes of the UK Corporate Governance Code, and PureTech confirms that there is no further information required to be disclosed pursuant to UK Listing Rule 6.4.8.

    About PureTech Health

    PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

    For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to PureTech's development plans and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240821665245/en/

    Get the next $KE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KE
    $PRTC

    CompanyDatePrice TargetRatingAnalyst
    PureTech Health plc
    $PRTC
    9/9/2024$58.00 → $45.00Outperform
    Leerink Partners
    Kimball Electronics Inc.
    $KE
    8/15/2024Buy → Neutral
    Sidoti
    Kimball Electronics Inc.
    $KE
    10/9/2023$39.00Buy
    B. Riley Securities
    Kimball Electronics Inc.
    $KE
    6/15/2023$3.40Overweight
    Cantor Fitzgerald
    Kimball Electronics Inc.
    $KE
    5/11/2022$27.00Buy
    Lake Street
    PureTech Health plc
    $PRTC
    1/7/2022$76.00 → $70.00Outperform
    SVB Leerink
    PureTech Health plc
    $PRTC
    8/25/2021$74.00 → $76.00Outperform
    SVB Leerink
    More analyst ratings

    $KE
    $PRTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

      Research conducted in collaboration with IPF experts and the Pulmonary Fibrosis Foundation reveals critical gaps in diagnosis, treatment, and quality of life for people living with IPF Findings highlight the profound physical, emotional, and psychosocial burden of IPF and underscore urgent need for enhanced education, streamlined diagnosis, patient-focused treatment plans, and more effective therapies PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the publication of new research in BMC Pulmonary Medicine that provides a comprehensive

      5/9/25 7:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kimball Electronics Reports Q3 Results and Reiterates Guidance for Fiscal 2025 With Sales and Operating Income Expected at High-End of Range; Company Adds New Facility to Support Strategy to Drive Growth in the Medical CMO

      Third Quarter Fiscal 2025 Highlights Net sales totaled $374.6 million Operating income of $11.7 million, or 3.1% of net sales, adjusted operating income of 4.2% Inventory of $296.6 million, a reduction of $9.6 million from Q2 Cash generated by operating activities of $30.9 million, the fifth consecutive quarter of positive cash flow Borrowings on credit facilities of $178.8 million, a $26.2 million decrease from the second quarter, and down $116 million, or 40%, in the fiscal year Kimball Electronics, Inc. (NASDAQ:KE) today announced financial results for the third quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.busin

      5/6/25 5:31:00 PM ET
      $KE
      Electrical Products
      Technology
    • PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

      Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) Regulatory and strategic planning underway to advance deupirfenidone into Phase 3 development PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the Company will deliver a late-breaking oral presentation at the upcoming American Thoracic Society (ATS) International Conference, taking place in San Francisco, California, from May 16-21, 2025.

      5/1/25 7:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KE
    $PRTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Director Phillips Richard D converted options into 7,672 shares and covered exercise/tax liability with 3,656 shares, increasing direct ownership by 51% to 11,827 units (SEC Form 4)

      4 - Kimball Electronics, Inc. (0001606757) (Issuer)

      1/6/25 3:26:06 PM ET
      $KE
      Electrical Products
      Technology
    • Director Phillippy Robert J was granted 6,548 shares, increasing direct ownership by 132% to 11,501 units (SEC Form 4)

      4 - Kimball Electronics, Inc. (0001606757) (Issuer)

      11/19/24 12:28:34 PM ET
      $KE
      Electrical Products
      Technology
    • SEC Form 4 filed by Director Thaxton Gregory A

      4 - Kimball Electronics, Inc. (0001606757) (Issuer)

      11/19/24 10:50:53 AM ET
      $KE
      Electrical Products
      Technology

    $KE
    $PRTC
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Appoints Peel Hunt as Joint UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed Peel Hunt as Joint UK Corporate Broker alongside UBS. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeut

      4/9/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • PureTech Appoints UBS as UK Corporate Broker

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, includ

      1/6/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KE
    $PRTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kimball Electronics Inc.

      SC 13G/A - Kimball Electronics, Inc. (0001606757) (Subject)

      11/12/24 3:47:56 PM ET
      $KE
      Electrical Products
      Technology
    • SEC Form SC 13G filed by PureTech Health plc

      SC 13G - PureTech Health plc (0001782999) (Subject)

      11/12/24 1:29:13 PM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PureTech Health plc

      SC 13G/A - PureTech Health plc (0001782999) (Subject)

      11/7/24 9:47:57 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KE
    $PRTC
    Financials

    Live finance-specific insights

    See more
    • Kimball Electronics Reports Q3 Results and Reiterates Guidance for Fiscal 2025 With Sales and Operating Income Expected at High-End of Range; Company Adds New Facility to Support Strategy to Drive Growth in the Medical CMO

      Third Quarter Fiscal 2025 Highlights Net sales totaled $374.6 million Operating income of $11.7 million, or 3.1% of net sales, adjusted operating income of 4.2% Inventory of $296.6 million, a reduction of $9.6 million from Q2 Cash generated by operating activities of $30.9 million, the fifth consecutive quarter of positive cash flow Borrowings on credit facilities of $178.8 million, a $26.2 million decrease from the second quarter, and down $116 million, or 40%, in the fiscal year Kimball Electronics, Inc. (NASDAQ:KE) today announced financial results for the third quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.busin

      5/6/25 5:31:00 PM ET
      $KE
      Electrical Products
      Technology
    • Kimball Electronics, Inc. Announces Date For Reporting Third Quarter Fiscal Year 2025 Financial Results

      Kimball Electronics, Inc. (NASDAQ:KE) today announced that it will report third quarter fiscal year 2025 financial results on Tuesday, May 6, 2025, after the closing of the market. The company will host a conference call and live webcast to review the results on Wednesday, May 7, 2025, at 10:00 a.m. Eastern Time. The telephone number to access the conference call is 877-407-8293 / +1 201-689-8349. A live webcast of the conference call can be accessed at investors.kimballelectronics.com. For those unable to participate in the live webcast, a replay will be archived at investors.kimballelectronics.com. About Kimball Electronics, Inc. Kimball Electronics is a global, multifaceted manufa

      4/23/25 3:26:00 PM ET
      $KE
      Electrical Products
      Technology
    • PureTech Health: Notice of Results

      PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2024, on Wednesday, April 30, 2025. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a b

      4/23/25 2:00:00 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KE
    $PRTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners resumed coverage on PureTech Health plc with a new price target

      Leerink Partners resumed coverage of PureTech Health plc with a rating of Outperform and set a new price target of $45.00 from $58.00 previously

      9/9/24 7:42:36 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kimball Electronics downgraded by Sidoti

      Sidoti downgraded Kimball Electronics from Buy to Neutral

      8/15/24 7:57:54 AM ET
      $KE
      Electrical Products
      Technology
    • B. Riley Securities initiated coverage on Kimball Electronics with a new price target

      B. Riley Securities initiated coverage of Kimball Electronics with a rating of Buy and set a new price target of $39.00

      10/9/23 8:30:28 AM ET
      $KE
      Electrical Products
      Technology

    $KE
    $PRTC
    SEC Filings

    See more
    • SEC Form 10-Q filed by Kimball Electronics Inc.

      10-Q - Kimball Electronics, Inc. (0001606757) (Filer)

      5/7/25 5:13:26 PM ET
      $KE
      Electrical Products
      Technology
    • Kimball Electronics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kimball Electronics, Inc. (0001606757) (Filer)

      5/6/25 5:24:54 PM ET
      $KE
      Electrical Products
      Technology
    • SEC Form 20-F filed by PureTech Health plc

      20-F - PureTech Health plc (0001782999) (Filer)

      4/30/25 10:43:35 AM ET
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care